AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Investors sue 89bio, Barinthus Biotherapeutics, and Roche over merger deal.
ByAinvest
Wednesday, Oct 8, 2025 11:30 am ET1min read
Brodsky & Smith is investigating 89bio's acquisition by Roche for $14.50 per share, plus a non-tradeable CVR of up to $6.00 per share. The investigation concerns whether the 89bio Board breached its fiduciary duties by failing to conduct a fair process and ensuring fair value for shareholders. Shareholders who wish to discuss the investigation can contact Jason Brodsky or Marc Ackerman at 855-576-4847.
Roche (RHHBY, RO.SW, ROG.SW) has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB) at $14.50 per share, plus a non-tradeable contingent value right (CVR) that could provide additional milestone-based payments of up to $6.00 per share [1]. The offer is being made pursuant to a previously announced merger agreement dated September 17, 2025 [1].However, Halper Sadeh LLC, an investor rights law firm, is investigating the transaction, alleging potential violations of federal securities laws and breaches of fiduciary duties by the 89bio Board [2]. The investigation concerns whether the Board failed to conduct a fair process and ensure fair value for shareholders. Shareholders who wish to discuss the investigation can contact Jason Brodsky or Marc Ackerman at 855-576-4847 [2].
The tender offer period will expire on October 29, 2025, unless extended. Roche's acquisition of 89bio, a biotechnology company focused on the development of cell therapies, is expected to enhance Roche's capabilities in this area [1]. The CVR component of the offer provides an additional layer of potential value to shareholders, contingent on the achievement of specified milestones.
Investors and shareholders are advised to carefully review the terms of the offer and consider seeking legal advice if they have concerns about the fairness and value of the transaction. The investigation by Halper Sadeh LLC highlights the importance of transparency and fairness in corporate acquisitions, particularly in the biotechnology sector.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet